Immunicon Corporation Announces Availability of Fluorescence In-Situ Hybridization Product Portfolio

New Repeat-Free(TM) Probes Available for FISH testing

HUNTINGDON VALLEY, Pa.–Immunicon Corporation (NASDAQ:IMMC – News) announced today the availability of a new product portfolio for Fluorescence In-Situ Hybridization (FISH) testing. The new RF Poseidon™ FISH Probes are available to the life science and diagnostic clinical laboratories.

FISH probes are used to detect gene amplification, gene rearrangements, microdeletions, chromosome duplications and other genetic abnormalities. “By eliminating the repeat sequences in the FISH probes, the RF Poseidon FISH probes allow for a faster hybridization, reduces background and provides more crisp signals than current probes,” stated Leon Terstappen, MD, PhD, Chief Scientific Officer, Immunicon Corporation. “Additionally, we believe the faster assays allow scientists and laboratorians the flexibility to obtain results in about 75% less time than current practices today.”

“The addition of the RF Poseidon FISH probe portfolio to Immunicon’s products expands our molecular diagnostics offering to customers,” said Byron Hewett, President & CEO, Immunicon Corporation. “It allows Immunicon to fully expand into rare cell testing arenas where we believe there are increasing medical needs.”

The RF Poseidon FISH Probes are developed using the proprietary Repeat-Free™ technology developed by Immunicon and the ULS labeling system developed by Kreatech Diagnostics, the Netherlands. The FISH probes are sold by Immunicon Corporation in North America and manufactured and sold by Kreatech Diagnostics in the rest of the world under an agreement entered into by Immunicon and Kreatech in April 2007.

Fluorescence In-Situ Hybridization (FISH)

Fluorescence In-Situ Hybridization is a technique used to look at chromosomes (the parts of the cell that contain genetic information in the form of DNA) or genes (specific regions of DNA in chromosomes that make RNA and proteins). Pieces of DNA containing a fluorescent dye are labeled and added to cells on a glass slide. When viewed under a fluorescent microscope, parts of chromosomes or genes that bind the pieces of DNA show up as colored. FISH is routinely used in an increasing number of molecular diagnostic areas, including disease diagnosis, therapeutic targeting, drug development, gene mapping and karyotyping analysis. FISH specifically is used to detect gene amplification, gene rearrangements, microdeletions, chromosome duplications and viral infections.

About Immunicon Corporation

Immunicon Corporation is developing and commercializing proprietary cell- and molecular-based human diagnostic and life science research products, and is providing certain analytical services to pharmaceutical and biotechnology companies to assist them in developing new therapeutic agents, with an initial focus on cancer disease management. Immunicon has developed platform technologies to identify, count and characterize a small number of rare cells in blood, such as circulating tumor cells and circulating endothelial cells that are important in many diseases and biological processes. Immunicon’s products and underlying technology platforms also have application in the clinical development of cancer drugs and in cancer research and may have applications in other fields of medicine, such as cardiovascular and infectious diseases. For more information, visit or

Forward-Looking Statements

The information contained in this press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often preceded by words such as “hope,” “may,” “believe,” “anticipate,” “plan,” “expect,” “intend,” “assume,” “will” and similar expressions. Forward-looking statements contained in this press release include, among others, statements relating to Immunicon’s key product and clinical development programs, the anticipated clinical utility of Immunicon’s products, and other statements not of historical fact. Immunicon cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Forward-looking statements speak only as of the date of this press release, reflect management’s current expectations and involve certain factors, such as risks and uncertainties that may cause actual results to be far different from those suggested by Immunicon’s forward-looking statements. These factors include, but are not limited to, risks and uncertainties associated with adequate financing of Immunicon to continue as a going-concern; Immunicon’s dependence on Veridex, LLC, a Johnson & Johnson company; the risks and uncertainties associated with the arbitration proceeding with Veridex and the award in favor of Veridex given Immunicon’s dependence on Veridex; research and development and clinical trial expenditures; commercialization of Immunicon’s product candidates; Immunicon’s ability to use licensed products and to obtain new licenses from third parties; Immunicon’s ability to manage its growth; obtaining necessary regulatory approvals; reliance on third party manufacturers and suppliers; reimbursement by third party payors to Immunicon’s customers for Immunicon’s products; risks and uncertainties associated with Immunicon’s outstanding convertible notes and warrants; compliance with applicable manufacturing standards; the ability to earn license and milestone payments under Immunicon’s agreement with Veridex; retaining key management or scientific personnel; delays in the development of new products or to planned improvements to Immunicon’s products; effectiveness of Immunicon’s products compared to competitors’ products; protection of Immunicon’s intellectual property and other proprietary rights; conflicts with the intellectual property of third parties; product liability lawsuits that may be brought against Immunicon; labor, contract or technical difficulties; and competitive pressures in Immunicon’s industry. These factors are discussed in more detail in Immunicon’s filings with the Securities and Exchange Commission. Except as required by law, Immunicon accepts no responsibility for updating the information contained in this press release beyond the published date, whether as a result of new information, future events or otherwise, or for modifications made to this document by Internet or wire services. “Immunicon” and the Immunicon Corporation logo are registered trademarks of Immunicon Corporation. Repeat-Free and CellTracks are trademarks of Immunivest Corporation, a wholly-owned subsidiary of Immunicon Corporation. All other trademarks or servicemarks appearing herein are the property of their respective holders. ALL RIGHTS RESERVED.

< | >